期刊
CANCERS
卷 9, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/cancers9090110
关键词
integrin; therapy; clinical trial; efficacy; health care economics
类别
资金
- MRC [G0800825] Funding Source: UKRI
- Cancer Research UK [21624, 17764, 16880] Funding Source: researchfish
- Medical Research Council [G0800825] Funding Source: researchfish
- Rosetrees Trust [M387] Funding Source: researchfish
- Medical Research Council [G0800825] Funding Source: Medline
Integrins are transmembrane receptors that are central to the biology of many human pathologies. Classically mediating cell-extracellular matrix and cell-cell interaction, and with an emerging role as local activators of TGF beta, they influence cancer, fibrosis, thrombosis and inflammation. Their ligand binding and some regulatory sites are extracellular and sensitive to pharmacological intervention, as proven by the clinical success of seven drugs targeting them. The six drugs on the market in 2016 generated revenues of some US$3.5 billion, mainly from inhibitors of alpha 4-series integrins. In this review we examine the current developments in integrin therapeutics, especially in cancer, and comment on the health economic implications of these developments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据